Sign up for Scientific Inquirer’s Steady State Newsletter for the week’s top stories, exclusive interviews, and weekly giveaways. Plenty of value added but without the tax. http://bit.ly/2VEF06u
Developing safe and efficient bioformulations using approved materials and ingenious designs can accelerate the clinical translation process.
Scientists from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have developed a new therapeutic tumor vaccine based on self-healing polylactic acid microcapsules, which can efficiently activate the immune system and inhibit tumor development.
This research was published in Science Advances.
Therapeutic cancer vaccines that harness the immune system to reject cancer cells have shown great promise for tumor treatment.
The research team, led by Prof. MA Guanghui and Prof. WEI Wei from IPE, already designed and fabricated a variety of tumor vaccines in their previous work. Theses vaccines have been proven effective in different tumor models, such as lymphoma, melanoma and breast cancer.
The researchers were impelled to improve the earlier tumor vaccines, however, due to certain limitations. For example, Prof. MA said that an unfavorable immunization microenvironment, along with a complicated preparation process and the need for frequent vaccinations significantly compromised their performance. “Therefore, we designed a novel microcapsule-based formulation for high-performance cancer vaccinations,” said Prof. MA.
This study represents the first time researchers used self-healing microcapsules with post-encapsulation, multiple loading, and efficient modulation of immunization microenvironments in a tumor vaccine.
The special self-healing feature provides a mild and efficient paradigm for antigen microencapsulation. After vaccination, these microcapsules create a favorable immunization microenvironment in situ, wherein antigen release kinetics, recruited cell behavior and acid surrounding environment work in a synergetic manner.
Owing to synergetic effects, the vaccine succeeds in increasing antigen utilization, improving antigen presentation and activating antigen presenting cells. “As a result, effective T cell response, potent tumor inhibition, anti-metastatic effects and prevention of postsurgical recurrence are achieved with various types of antigens in different tumor models,” said Prof. WEI.
Moreover, the researchers verified the availability of the novel vaccine platform used in the neoantigen vaccine, which conforms to precision medicine, said Prof. WEI. Due to the simple post-encapsulation process, the clinicians were able to prepare the neoantigen formulation by themselves at any time.
IMAGE SOURCE: Creative Commons
Words matter. Images matter. The Scientific Inquirer needs your support. Help us pay our contributors for their hard work. Visit our Patreon page and discover ways that you can make a difference. http://bit.ly/2jjiagi